Non-small-cell Lung Cancer Clinical Trial
Official title:
Role of SPECT in Radiotherapy Treatment Planning and Toxicity Evaluation for the Patients With Stage I-III NSCLC
Overall objective of the study is to compare the use of SPECT in radiotherapy treatment planning with standard CT-based radiotherapy for stage I-III non-small-cell lung cancer patients
Primary objective:
-To compare the rate of grade 2 or higher pneumonitis amongst patients with stage III NSCLC
treated with radiotherapy using SPECT in radiotherapy treatment planning versus standard
CT-based radiotherapy planning;
Secondary Objectives:
- To evaluate SPECT as a tool to predict lung toxicity;
- To establish estimates for the incidence and severity of pulmonary tissue effects
observed in stage III NSCLC patients treated with radiotherapy;
- To generate hypotheses for subsequent use of SPECT-CT-based treatment planning as a
method for minimization of toxicity risks
- To generate hypotheses for modeling studies of SPECT-CT-based treatment planning for
dose-escalation;
- To compare the loco-regional control, time to progression and overall survival of
patients treated with SPECT-based plan versus standard CT-based plan
- To compare the quality of life in patients randomized to the two study arms.
This trial is a single centre observational study. All patients will irrespective of their
registration in the trial receive radiotherapy according to the standard treatment regimen at
the Department of Oncology, Aarhus University Hospital. Participation implies baseline and
follow-up procedures. In the treatment planning phase patients will be randomized to one of
the following arms: Arm 1 SPECT/CT-based treatment plan with functional dose-volume
parameters and Arrm 2 Standard CT-based plan with conventional dose-volume parameters.
The trial will consist of two parts. To initiate the trial a pilot study (part 1) will be
performed to determine the feasibility in our setting at Aarhus University Hospital as it is
described in the literature. Consecutive patients will be enrolled in the pilot study during
1-year period. The interim analysis after one year of enrollment will be performed to
determine what patients are most likely to benefit from functional radiotherapy planning
based on SPECT. The main objective of this part is to determine whether V/Q-SPECT data are
valid and usable in the radiotherapy planning. The timing for acute and late follow-up SPECT
will be determined. Randomized trial (part 2) will be performed thereafter.
Statistical analysis. The randomization by permitted blocks method will be used to allocate
patients to treatment arm. Stratification factors will be age, gender, disease stage,
histology, concurrent chemotherapy and irradiated volumes.
The chi-squire test (α=0.10) with the continuity correction will be used for analysis of the
primary analysis. For all other comparisons, two-sided analyses will be performed and a
p-value of 0.05 or less will be considered statistically significant. 95% confidence
intervals will be constructed for outcomes of interest. Descriptive statistics will be used
to summarize patient characteristics and outcomes by intervention arm. Differences in
outcomes between intervention arms will be compared by using paired t-tests, Wilcoxon rank
sum tests or McNemar tests as appropriate. Adjusting for stratification factors will be
performed using logistic regression or linear regression. Time-to-event analyses will be
estimated using the Kaplan-Meier method, and compared using Cox proportional hazards
regression.
Estimation of the relationship between dose-volume parameters and toxicity will be evaluated
using logistic regression analyses. Within patients who were planned using SPECT, the
association between dose-volume parameters calculated using SPECT and those calculated under
a CT-plan will be evaluated using correlation coefficients.
All patients who are randomized will be included in the analysis of safety and efficacy
outcomes. Secondary analyses may be performed on those patients only on those who received
radiotherapy as per the treatment plan based on SPECT or CT as per the intervention arm. Any
patient who is randomized but does not receive radiotherapy based on the intervention
allocated treatment plan will be described in detail along with the reason for not receiving
the prescribed plan.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02495233 -
A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT02672358 -
Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC
|
Phase 2 | |
Recruiting |
NCT05815472 -
Advanced Patient Monitoring and A.I. Supported Outcomes Assessment in Lung Cancer Using Internet of Things Technologies (A.I. - APALITT)
|
N/A | |
Not yet recruiting |
NCT05900219 -
Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study
|
Phase 2 | |
Not yet recruiting |
NCT04560244 -
A Trial of SHR1701 Combined With Radiotherapy for Metastatic Non-small Cell Lung Cancer Failure After First-line Treatment
|
Phase 2 | |
Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
Completed |
NCT01924416 -
Lung Cancer Information Study (LCIS-R01)
|
N/A | |
Completed |
NCT01136083 -
Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients
|
N/A | |
Completed |
NCT00831454 -
Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection
|
N/A | |
Completed |
NCT00363766 -
Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00913705 -
Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01124864 -
A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy.
|
Phase 2 | |
Completed |
NCT01383135 -
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
|
Early Phase 1 | |
Completed |
NCT00049998 -
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
|
Phase 3 | |
Terminated |
NCT05061537 -
Study of PF-07263689 in Participants With Selected Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT03320044 -
Early Diagnosis of Small Pulmonary Nodules by Multi-omics Sequencing
|
||
Recruiting |
NCT04895930 -
Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC
|
Phase 2 | |
Recruiting |
NCT03267654 -
Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 | |
Recruiting |
NCT04401059 -
Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective Study
|
Phase 4 | |
Not yet recruiting |
NCT02930954 -
Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance
|
Phase 2 |